RT Journal Article
SR Electronic
T1 Tau-Neurodegeneration <em>mismatch</em> reveals vulnerability and resilience to comorbidities in Alzheimer’s continuum
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.12.23285594
DO 10.1101/2023.02.12.23285594
A1 Lyu, Xueying
A1 Duong, Michael Tran
A1 Xie, Long
A1 de Flores, Robin
A1 Richardson, Hayley
A1 Hwang, Gyujoon
A1 Wisse, L.E.M.
A1 DiCalogero, Michael
A1 McMillan, Corey T.
A1 Robinson, John L.
A1 Xie, Sharon X.
A1 Grossman, Murray
A1 Lee, Edward B.
A1 Irwin, David J.
A1 Dickerson, Bradford C.
A1 Davatzikos, Christos
A1 Nasrallah, Ilya M.
A1 Yushkevich, Paul A.
A1 Wolk, David A.
A1 Das, Sandhitsu R.
A1 Alzheimer’s Disease Neuroimaging Initiative
YR 2023
UL http://medrxiv.org/content/early/2023/02/15/2023.02.12.23285594.abstract
AB Variability in the relationship of tau-based neurofibrillary tangles (T) and degree of neurodegeneration (N) in Alzheimer’s Disease (AD) is likely attributable to the non-specific nature of N, which is also modulated by such factors as other co-pathologies, age-related changes, and developmental differences. We studied this variability by partitioning patients within the Alzheimer’s continuum into data-driven groups based on their regional T-N dissociation, which reflects the residuals after the effect of tau pathology is “removed”. We found six groups displaying distinct spatial T-N mismatch and thickness patterns despite similar tau burden. Their T-N patterns resembled the neurodegeneration patterns of non-AD groups partitioned on the basis of z-scores of cortical thickness alone and were similarly associated with surrogates of non-AD factors. In an additional sample of individuals with antemortem imaging and autopsy, T-N mismatch was associated with TDP-43 co-pathology. Finally, T-N mismatch training was then applied to a separate cohort to determine the ability to classify individual patients within these groups. These findings suggest that T-N mismatch may provide a personalized approach for determining non-AD factors associated with resilience/vulnerability to Alzheimer’s disease.Competing Interest StatementDavid Wolk has served as a paid consultant to Eli Lilly, GE Healthcare, and Qynapse. He serves on a DSMB for Functional Neuromodulation. He is a site investigator for a clinical trial sponsored by Biogen.Dr. Xie received personal consulting fees from Galileo CDS, Inc. Dr. Xie has become an employee of Siemens Healthineers since May 2022 but the current study was conducted during his employment at the University of Pennsylvania.Ilya Nasrallah has served as the speakers bureau to Biogen and advisory board to Eisai.Corey McMillan receives an honorarium as Associate Editor of NeuroImage:Clinical.Funding StatementThe study was supported by the funding R01 AG056014, RF1 AG069474, P01AG066597, P30AG072979, and U19AG062418. This study was also supported by MultiPark - A Strategic Research Area at Lund University. The AVID cohort was sponsored by Avid Radiopharmaceuticals. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Pennsylvania IRB gave ethical approval for all participants from the University of Pennsylvania.For the deidentified ADNI and Avid Radiopharmaceuticals multisite data, each institutional review board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study may be available upon reasonable request to the authors